Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff - a multicenter analysis.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
06 2019
Historique:
received: 24 02 2019
revised: 30 03 2019
accepted: 08 04 2019
entrez: 4 6 2019
pubmed: 4 6 2019
medline: 6 2 2020
Statut: ppublish

Résumé

Laparoscopic/robotic radical hysterectomy has been historically considered oncologically equivalent to open radical hysterectomy for patients with early cervical cancer. However, a recent prospective randomized trial (Laparoscopic Approach to Cervical Cancer, LACC) has demonstrated significant inferiority of the minimally invasive approach. The aim of this study is to evaluate the oncologic outcomes of combined laparoscopic-vaginal radical hysterectomy. Between August 1994 and December 2018, patients with invasive cervical cancer were treated using minimally-invasive surgery at the Universities of Jena, Charité Berlin (Campus CCM and CBF) and Cologne and Asklepios Clinic Hamburg. 389 patients with inclusion criteria identical to the LACC trial were identified. In contrast to the laparoscopic/robotic technique used in the LACC trial, all patients in our cohort underwent a combined transvaginal-laparoscopic approach without the use of any uterine manipulator. A total of 1952 consecutive patients with cervical cancer were included in the analysis. Initial International Federation of Gynecology and Obstetrics (FIGO) stage was IA1 lymphovascular space invasion (LVSI+), IA2 and IB1/IIA1 in 32 (8%), 43 (11%), and 314 (81%) patients, respectively, and histology was squamous cell in 263 (68%), adenocarcinoma in 117 (30%), and adenosquamous in 9 (2%) patients. Lymphovascular invasion was confirmed in 106 (27%) patients. The median number of lymph nodes was 24 (range 2-86). Lymph nodes were tumor-free in 379 (97%) patients. Following radical hysterectomy, 71 (18%) patients underwent adjuvant chemoradiation or radiation. After a median follow-up of 99 (range 1-288) months, the 3-, 4.5-, and 10-year disease-free survival rates were 96.8%, 95.8%, and 93.1 %, and the 3-, 4.5-, and 10-year overall survival rates were 98.5%, 97.8%, and 95.8%, respectively. Recurrence location was loco-regional in 50% of cases with recurrence (n=10). Interestingly, 9/20 recurrences occurred more than 39 months after surgery. The combined laparoscopic-vaginal technique for radical hysterectomy with avoidance of spillage and manipulation of tumor cells provides excellent oncologic outcome for patients with early cervical cancer. Our retrospective data suggest that laparoscopic-vaginal surgery may be oncologically safe and should be validated in further randomized trials.

Identifiants

pubmed: 31155516
pii: ijgc-2019-000388
doi: 10.1136/ijgc-2019-000388
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

845-850

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Christhardt Kohler (C)

Department of Gynecology, Medical Faculty of the University of Cologne, Koln, Germany ch.koehler@asklepios.com.
Department of Special Operative and Oncologic Gynecology, Asklepios Klinik Altona, Hamburg, Germany.

Hermann Hertel (H)

Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany.

Jörg Herrmann (J)

Department of Obstetrics and Gynecology, Sophien und Hufeland Klinikum, Weimar, Germany.

Simone Marnitz (S)

Department of Radiooncology, Medical Faculty of the University of Cologne, Koln, Germany.

Peter Mallmann (P)

Department of Gynecology, Medical Faculty of the University of Cologne, Koln, Germany.

Giovanni Favero (G)

Department of Gynecology, HELIOS Mariahilf Klinik Hamburg, Hamburg, Germany.

Andrea Plaikner (A)

Department of Special Operative and Oncologic Gynecology, Asklepios Klinik Altona, Hamburg, Germany.

Peter Martus (P)

Institute for Clinical Epidemiology and Biometry, Eberhard Karls University Tübingen Faculty of Medicine, Tubingen, Germany.

Mieczyslaw Gajda (M)

Institute for Pathology, Friedrich-Schiller-University of Jena Faculty of Medicine, Jena, Germany.

Achim Schneider (A)

Center for Dysplasia and Cytology, MVZ Fürstenbergkarree Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH